Top Markets
#1 Black Phoenix Black Phoenix +166.82%
#2 Islamic Coin Islamic Coin +158.16%
#3 Glidr Glidr +84.34%
#4 Acurast Acurast +29.06%
#5 Cryptopia Cryptopia +20.92%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +18.86%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.84%
#8 Test Test +13.79%
#9 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +10.94%
#10 Bluwhale Bluwhale +10.65%
Coin of the day
Black Phoenix Black Phoenix
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Nanomix Corporation Nanomix Corporation

Nanomix Corporation

NNMX
Classifica tra le azioni #41810
Boston Therapeutics, Inc. focuses on the discovery, production, and... Boston Therapeutics, Inc. focuses on the discovery, production, and commercialization of therapeutic drugs aimed at fulfilling critical unmet medical needs in the areas of diabetes and inflammatory diseases. The company's pipeline features BTI-320, a non-systemic, carbohydrate-based tablet currently in Phase II clinical trials, which is being developed to reduce post-meal blood glucose levels in patients with pre-diabetes and type 2 diabetes. They also have IPOXYN, an injectable medication designed to prevent tissue necrosis and address conditions caused by low oxygen, such as diabetic foot ulcers and other related vascular or neurological complications. Additionally, Boston Therapeutics is progressing with BTI-410, a peptide injectable compound also in Phase II clinical development, intended to stimulate beta cell maturation in the pancreas. This could potentially serve as a new insulin-producing cell agent for individuals with type 2 diabetes and type 1 patients on immunosuppression therapy following a kidney transplant. Complementing its pharmaceutical endeavors, the company offers SUGARDOWN, a non-systemic, polysaccharide-based dietary supplement designed to support healthy blood glucose management, and OXYFEX, a veterinary application that acts as an oxygen delivery agent, similar to a red blood cell replacement, for treating ischemia, trauma, and blood loss during surgical procedures. The firm further extends its offerings to include Automatic Retinal Image Analysis (ARIA), a diagnostic tool used for screening cardiovascular risks, including stroke. Boston Therapeutics, Inc. maintains its headquarters in Lawrence, Massachusetts.
Prezzo delle azioni
$0.0002
Ultima sincronizzazione: 2025-04-08
Capitalizzazione di mercato
$9.80K
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Nanomix Corporation (NNMX)

Categoria

Healthcare
Utile per Nanomix Corporation (NNMX)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Nanomix Corporation, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Nanomix Corporation dal 2026 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
Non abbastanza dati per le date fornite.
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
$7.51B -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
$5.15B -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
$5.56B -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
$3.86B -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
$1.42B -
US